IPM clocks Rs 116393 cr in October ’17

Anti-infective therapy was valued at Rs 1431 crores

The Indian Pharmaceutical Market (IPM) clocked Rs 116393 crores of which the retail sector was valued at Rs 98195 crores as of MAT October 2017 with a growth of 5 per cent over last year. On a monthly basis, however, retail has shown a strong improvement with a growth of 10 per cent over October 2016 while the entire IPM has also grown at a similar pace of 9 per cent over same period last year (SPLY). This is an indicator of the revival of Indian pharma market post GST where the growth has improved slowly over the last three months.’

Top 10 companies continue to dominate with a share of 43 per cent IPM and these top companies have grown at par with the IPM at 9 per cent SPLY. The top 150 companies continued to account for 98 per cent of IPM on MAT and month basis whereas Top 20 companies also maintained a share of 64 per cent in both MAT and month level. Lupin with a growth of 10per cent is still the fastest growing company among the Top 10 on MAT basis whereas on a monthly basis, Mankind has shown the strongest growth of 15 per cent. Except Zydus Cadila, all the Top 10 companies showed positive growth on MAT. Companies in 11-20 bracket have shown a much slower combined growth which is mainly due to Pfizer’s growth of -13per cent and DRL showing no growth on SPLY. However, companies like IPCA (12 per cent), Glenmark (10 per cent), Aristo (9 per cent) and USV (8 per cent) have shown good growth.

Top 10 brands in the IPM were valued at Rs 332 crores combined and showed a slightly slower than market growth of 8 per cent for the month of October 2017. The performance of Top 10 brands has been mixed with some brands like Augmentin (29 per cent), Lantus (25 per cent) and Spasmo-proxyvon + (23 per cent) performing strongly whereas others like Mixtard (0 per cent), Glycomet-GP (4 per cent) and Monocef (2 per cent), which are in fact in Top 5 all showing substandard growths.

A major change in the list of top 10 brands as compared to October 2016 is exit of Galvus-Met and Corex whose place is taken by Spasmo-proxyvon + and Clavam. Brands ranked 11-20 grew better than IPM at combined growth of 12 per cent and were valued at Rs 251 crores. The strong growth was mainly due to Synflorix (64 per cent), Zinetac (37 per cent) and Liv-52 (24 per cent). However, Galvus Met (- 6 per cent) and Calpol (-2 per cent) were few brands, which also registered negative growth in this segment.

Indian companies increased their dominance in the IPM with their share now moving to 80 per cent for the month of October 2017 and grew at par with the IPM at 10 per cent. MNCs, however, showed a much slower growth at 5 per cent and also lost 1 per cent share to come down to 20 per cent share in the IPM. No. 1 MNC Abbott (5 per cent) recorded a slower than IPM growth whereas 4 of the top 10 MNCs – Pfizer (-13 per cent), Novartis (-4 per cent), Janssen (-7 per cent) and AstraZeneca (-8 per cent) showed a negative growth for the month. However, other Top 10 MNC companies like Eli Lilly (51 per cent) and GlaxoSmithKline (14 per cent) showed good progress. Top Indian company Sun also showed a slower growth of 5 per cent. All Top 10 Indian companies grew positively for the month of October 2017 with Mankind (15 per cent), Alkem (12 per cent), Intas (10 per cent) and Glenmark (10 per cent) all registering a double digit growth.

Acute therapy, with a growth of 8 per cent for the month of October 2017 for the first time in many months matched the growth of chronic therapy which grew at 9 per cent. Also, acute therapy continued to be have a 67 per cent share in IPM as compared to chronic’s 33 per cent share. Anti-infectives maintained its top position in the IPM for the month of October 2017 and its growth (4 per cent) has also shown improvement. Cardiac maintained its second position and registered a growth of 7 per cent on SPLY. Respiratory showed an improved growth of 7 per cent which might be due to start of winter in many parts of the country. Derma (18 per cent) continued its trend of the fastest growing top 10 therapy for the third time in row whereas anti-diabetic therapy (12 per cent) also continued its double digit growth, which was slightly dented by poor growth of its top brands.

Anti-infective therapy was valued at Rs 1431 crores for the month of October 2017 with a growth of 4 per cent. Most of the Top 10 molecules for the first time have shown positive growth with only Cefixime Oral Solids (-3 per cent) showing de-growth. Among Top 10 Amikacin with 20 per cent growth was the fastest growing molecule while the largest molecule Amoxycillin and Clavulanic Acid Solids also showed strong growth of 9 per cent for the first time in many months. Augmentin took over Monocef to become the No. 1 brand and registered a strong growth of 29 per cent. Other Top 10 brands which showed a strong growth are Mikacin (22 per cent) and Xone (26 per cent). However, two brands in this segment Taxim-O (-11 per cent) and Monocef-O (-8 per cent) showed de-growth.

Cardiac therapy continued to be the second ranked therapy in IPM clocking a revenue of Rs 1177 crores and a growth rate of 7 per cent on SPLY. Combinations with a growth of 13 per cent continue to drive growth in this therapy and grew three times faster than plain molecules which grew at only 4 per cent. While two of the Top 10 molecules Atorvastatin (-5 per cent) and Amlodipine (-12 per cent) showed de-growth, all other Top 10 molecules grew positively with Telmisrtan + HCT (10 per cent), Atenolol + Amlodipine (17 per cent), Amlodipine + Telmisartan (16 per cent) and Cilnidipine (17 per cent) growing at double digit. Rosuvastatin with a value of Rs 62 crores was the top molecule in the therapy with a growth of 3 per cent over SPLY. Telmisartan Combinations continued to grow strongly with 13 per cent growth. Six of the Top 10 brands showed double digit growth with Amlokind-AT and Cilacar (24 per cent) showing growth above 20 per cent. Only Minipress-XL (-6 per cent) and Clexane (-21 per cent) recorded de-growth among Top 10 brands.
Gastro intestinal therapy continued to be the third largest therapy in IPM with a value of Rs 1078 crores for the month with a growth of 9 per cent which is at par with the IPM. All top 10 molecules in the therapy except Omeprazole + Domperidome (-3 per cent) registered a positive growth. The largest molecule Pantoprazole + Domperidome clocked Rs 70 crore for the month and showed a double digit growth of 11 per cent. Bacillus Clausii continued to show progress with 43 per cent growth over SPLY. Other top molecules which showed strong growths are Oral Electrolytes (18 per cent) and Other Dicyclomine combinations (20 per cent). Spasmo-Proxyvon+ continued to be the top brand in the therapy with a robust growth of 23 per cent while Zinetac displaced Pan from the second spot and grew at 37 per cent for the month of October 2017. Among top 10 brands Aciloc (-5 per cent), Pantocid (-2 per cent) and Duphalac (-3 per cent) showed a negative growth.

Anti-diabetics maintained continued to be 4th ranked Therapy in the IPM and clocked a value of Rs 930 crores for the month of October 2017 and also continues to grow in double digits at 12 per cent on SPLY. Most top molecules showed a strong growth over SPLY with the top molecule Glimepiride + Metformin growing at 6 per cent. While DPP4 Inhibitors clocked a combined value of Rs 210 crores and grew at par with the therapy with a growth of 13 per cent, Metformin + Vildagliptin (-3 per cent) and Sitagliptin (-4 per cent) showed de-growth. SGLT-2 Inhibitors continued to grow strongly at 75 per cent but it was Metformin + Teneligliptin with a growth of 87 per cent which was the most progressive segment in the therapy. While top insulin brands like Mixtard (0 per cent) and Novomix (1 per cent) showed decreased growths, Huminsulin with 56 per cent growth was the fastest growing Top 10 brand followed by Lantus (25 per cent). Only Galvus Met (-6 per cent) showed a negative growth among Top 10 brands of the therapy.

Dermatology continued to be the fastest growing therapy in IPM with a growth of 18 per cent for the month of October 2017 and also clocked a revenue of Rs 827 crores for the month. While Emollients Protectives remains the largest sub category within the therapy with a value of Rs 83 crores and growth 7 per cent, Luliconazole (197 per cent) has jumped to rank 4 in the therapy for the month. The second largest molecule Itraconazole also continued its progression with a tremendous growth of 76 per cent over SPLY. While No. 1 brand Betadine de-grew at -3 per cent, 8 of the other top 10 brands grew in double digits with the likes of Panderm+ (46 per cent), Candiforce (54 per cent) and IT-Mac (92 per cent) recording a tremendous growths.